Refractory Malignant Neoplasm Active Not Recruiting Phase 1 Trials for Sorafenib (DB00398)

IndicationStatusPhase
DBCOND0074899 (Refractory Malignant Neoplasm)Active Not Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02143401Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid TumorsTreatment
NCT01531361Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF MutationsTreatment